RGBP — Regen BioPharma Share News
0.000.00%
Last trade - 00:00- $0.17m
- $1.07m
- $0.24m
Brief: Regen Biopharma Expands Vision For Phase 1 Clinical Trial Of Hemaxellerate
Brief: Regen Biopharma, Inc. Receives First Phase Of Confirmatory Study
Brief: Regen Biopharma Files Provisional Patent On Car-T Cell Capable Of Attracting And Educating Naïve T Cells
Brief: Regen Biopharma addresses potential impact of recent Bristol Myers Squibb's $2.3 billion acquisition of IFM Therapeutics
Brief: Regen Biopharma Inc research demonstrates ex-vivo immune suppression with novel nr2f6 activators
Brief: Regen Biopharma restructures management stock compensation
Brief: Regen BioPharma says cancer stem cell gene target key mediator of cancer immune surveillance